Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02016716 · ClinicalTrials.gov registry record · Phase 3
A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 294
- Enrollment target
NCT02016716 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 294 participants.
The verdict
NCT02016716, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 294 participants
- Enrollment target
Study Summary
The purpose of this study is to compare 2 formulations of romosozumab (AMG 785) on bone mineral density (BMD) in postmenopausal women with osteoporosis.
Interventions
- DRUG Romosozumab 90 mg/mL
- DRUG Placebo 90 mg/mL
- DRUG Romosozumab 70 mg/mL
- DRUG Placebo 70 mg/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2013-12-03 |
| Est. Completion | 2014-12-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02016716
The ClinicalTrials.gov registry entry for NCT02016716 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Romosozumab 90 mg/mL is the first listed.
NCT02016716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02016716 about?
NCT02016716 is a clinical study titled "A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis". The purpose of this study is to compare 2 formulations of romosozumab (AMG 785) on bone mineral density (BMD) in postmenopausal women with osteoporosis.
What is the current status of trial NCT02016716?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 294 participants. The study started on 2013-12-03. Estimated completion is 2014-12-08.
What interventions are being tested in trial NCT02016716?
The interventions under investigation include: Romosozumab 90 mg/mL (DRUG), Placebo 90 mg/mL (DRUG), Romosozumab 70 mg/mL (DRUG), Placebo 70 mg/mL (DRUG).
Who is sponsoring clinical trial NCT02016716?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.